Biotech Values

[caravon]

It became very popular lately to make very predictions and trial designs based on 4-15 patients. Celldex is not alone. There are many such bio/pharma companies.

The most interesting part is that, using bogus "few patients statistical methods", there are numbers of researchers seriously speaking about stat significant results. However, refractive/salvage patients' treatment statistics is a totally different matter since there is close to zero placebo-treatment benefits.